Orexigen appoints Dr Dennis Kim
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics (US) has appointed Dr Dennis Kim senior vice-president and head of obesity and metabolic disorders. Dr Kim was previously chief medical officer and vice-president of medical affairs at EnteroMedics. Orexigen has a potential obesity product Contrave (sustained-release naltrexone and bupropion) in Phase III clinical trials.